Copyright
©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Pharmacol Ther. Dec 6, 2012; 3(6): 97-99
Published online Dec 6, 2012. doi: 10.4292/wjgpt.v3.i6.97
Published online Dec 6, 2012. doi: 10.4292/wjgpt.v3.i6.97
Pyloric stenosis associated Crohn's disease responding to adalimumab therapy
Sameer Gaggar, Nicholas Thompson, Department of Gastroenterology, Freeman Hospital, NE7 7DN Newcastle, United Kingdom
John Scott, Department of Radiology, Freeman Hospital, NE7 7DN Newcastle, United Kingdom
Author contributions: Gaggar S collected data and prepared manuscript; Scott J provided radiology data and input; Thompson N revised manuscript.
Correspondence to: Dr. Sameer Gaggar, Department of Gastroenterology, Freeman Royal Hospital, NE7 7DN Newcastle, United Kingdom. sameergaggar@nhs.net
Received: June 8, 2012
Revised: October 8, 2012
Accepted: November 20, 2012
Published online: December 6, 2012
Revised: October 8, 2012
Accepted: November 20, 2012
Published online: December 6, 2012
Abstract
Gastroduodenal Crohn’s disease (CD) is rare and the response to standard medical therapy is often poor. Anti-tumor necrosis factor therapy has revolutionised the treatment of CD. We present a patient with pyloric stenosis associated with CD which improved with Adalimumab therapy. We recommend considering anti-tumor necrosis factor therapy in symptomatic gastroduodenal CD.